Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Atezolizumab +/- Talazoparib in SLFN11+ ES-SCLC
NCT04334941Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Started Jul 2020; status: active, not recruiting.
02
Drugs
talazoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04334941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334941.